Research led by scientists at UCLA Jonsson Comprehensive Cancer Center found that responses to PD-1 checkpoint blockade immunotherapy in patients with advanced melanoma depended on whether or not they had previously received another immunotherapy—CTLA-4 blockade—as well as other factors.
OS Therapies Inc. announced positive data from a phase IIb clinical trial (NCT04974008) of OST-HER2 (OST31-164)—the company’s HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma.
